279 related articles for article (PubMed ID: 18368132)
1. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
5. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.
Kiyohara E; Tamai K; Katayama I; Kaneda Y
Gene Ther; 2012 Jul; 19(7):734-41. PubMed ID: 21900962
[TBL] [Abstract][Full Text] [Related]
6. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
8. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
Trefzer U; Sterry W
Dermatology; 2005; 211(4):370-1. PubMed ID: 16286751
[No Abstract] [Full Text] [Related]
9. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
[TBL] [Abstract][Full Text] [Related]
10. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
11. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
Faião-Flores F; Quincoces Suarez JA; Fruet AC; Maria-Engler SS; Pardi PC; Maria DA
PLoS One; 2015; 10(3):e0118702. PubMed ID: 25742310
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
13. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
[TBL] [Abstract][Full Text] [Related]
14. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
15. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
Valero T; Steele S; Neumüller K; Bracher A; Niederleithner H; Pehamberger H; Petzelbauer P; Loewe R
J Invest Dermatol; 2010 Apr; 130(4):1087-94. PubMed ID: 19940857
[TBL] [Abstract][Full Text] [Related]
16. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.
Alteber Z; Azulay M; Cafri G; Vadai E; Tzehoval E; Eisenbach L
Cancer Immunol Immunother; 2014 Apr; 63(4):369-80. PubMed ID: 24452202
[TBL] [Abstract][Full Text] [Related]
17. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
19. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells.
Kunikata N; Sano K; Honda M; Ishii K; Matsunaga J; Okuyama R; Takahashi K; Watanabe H; Tamura G; Tagami H; Terui T
J Invest Dermatol; 2004 Aug; 123(2):395-402. PubMed ID: 15245441
[TBL] [Abstract][Full Text] [Related]
20. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
